Literature DB >> 35302308

茜璇 卢, 黎莎 包, 宗富 潘, 明华 葛.   

Abstract

（ATC），。，ATC（TAM）、TAM；T；。，1/1ATC，。ATC，ATC、，ATC，ATC。ATC。.

Entities:  

Keywords:  Anaplastic thyroid carcinoma; Clinical study; Immune escape; Immunotherapy; Review

Year:  2021        PMID： 35302308      PMCID： PMC8931605          DOI： 10.3724/zdxbyxb-2021-0273

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN： 1008-9292


  62 in total

Review 1.  SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.

Authors:  André Veillette; Jun Chen
Journal:  Trends Immunol       Date:  2018-01-11       Impact factor: 16.687

2.  The combination of a novel immunomodulator with a regulatory T cell suppressing antibody (DTA-1) regress advanced stage B16F10 solid tumor by repolarizing tumor associated macrophages in situ.

Authors:  Sayantan Banerjee; Kuntal Halder; Sweta Ghosh; Anamika Bose; Subrata Majumdar
Journal:  Oncoimmunology       Date:  2015-01-30       Impact factor: 8.110

3.  Impact of tumor-associated macrophages and BRAFV600E mutation on clinical outcomes in patients with various thyroid cancers.

Authors:  Jae Won Cho; Won Woong Kim; Yu-Mi Lee; Min Ji Jeon; Won Gu Kim; Dong Eun Song; Yangsoon Park; Ki-Wook Chung; Suck Joon Hong; Tae-Yon Sung
Journal:  Head Neck       Date:  2019-01-19       Impact factor: 3.147

Review 4.  Biologic and Clinical Perspectives on Thyroid Cancer.

Authors:  James A Fagin; Samuel A Wells
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

5.  Interactive role of miR-126 on VEGF-A and progression of papillary and undifferentiated thyroid carcinoma.

Authors:  Ali Salajegheh; Haleh Vosgha; Md Atiqur Rahman; Moein Amin; Robert Anthony Smith; Alfred King-Yin Lam
Journal:  Hum Pathol       Date:  2016-01-07       Impact factor: 3.466

6.  Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.

Authors:  John W Kunstman; C Christofer Juhlin; Gerald Goh; Taylor C Brown; Adam Stenman; James M Healy; Jill C Rubinstein; Murim Choi; Nimrod Kiss; Carol Nelson-Williams; Shrikant Mane; David L Rimm; Manju L Prasad; Anders Höög; Jan Zedenius; Catharina Larsson; Reju Korah; Richard P Lifton; Tobias Carling
Journal:  Hum Mol Genet       Date:  2015-01-09       Impact factor: 5.121

Review 7.  Oncolytic virotherapy.

Authors:  Stephen J Russell; Kah-Whye Peng; John C Bell
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

8.  Macrophage Densities Correlated with CXC Chemokine Receptor 4 Expression and Related with Poor Survival in Anaplastic Thyroid Cancer.

Authors:  Dae In Kim; Eunyoung Kim; Young A Kim; Sun Wook Cho; Jung Ah Lim; Young Joo Park
Journal:  Endocrinol Metab (Seoul)       Date:  2016-08-02

9.  Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.

Authors:  Christian M Schürch; Matthias A Roelli; Stefan Forster; Marie-Hélène Wasmer; Frido Brühl; Renaud S Maire; Sergio Di Pancrazio; Marc-David Ruepp; Roland Giger; Aurel Perren; Anja M Schmitt; Philippe Krebs; Roch-Philippe Charles; Matthias S Dettmer
Journal:  Thyroid       Date:  2019-05-10       Impact factor: 6.568

10.  DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization.

Authors:  Charlene M Downey; Mehrnoosh Aghaei; Reto A Schwendener; Frank R Jirik
Journal:  PLoS One       Date:  2014-06-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.